Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


REMS Website Will Name, Not Shame, Potential Abusers – Gottlieb

Executive Summary

US FDA will list number of inquiries about acquiring samples for generic drug development, and also whether FDA sends letters to brand companies telling them it is safe to provide the generic sponsor with the samples. 

Related Content

REMS Abuse Website: All Sizzle, No Steak?
Generic Company Disclosure Could Be A 'Speedbump' Against Misuse Of US FDA Access Inquiry List
Shared REMS: US FDA Wants Brisk Brand-Generic Talks, Might Give Unilateral Waivers
REMS Abuse Website: Celgene, Actelion Top List Of Suspected 'Gamers'
Initiator Or Facilitator? Gottlieb Reflects On First Year As Head Of US FDA
Gottlieb: Real Risk Of Congressional Action If Anti-Competitive Actions Continue
US FDA Biosimilar Guidance Update Will Relax Interchangeability Standards
CDER Director Woodcock Plans Changes To Drug Reviews During OND Transition





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts